Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Chinese Biopharma Stocks Surge on U.S. Regulatory Openness; Innovent +6-7%, Akeso +8%, CSPC +6% as Treasury Drafts Pharma Licensing Rules

by Team Lumida
September 21, 2026
in Equities
Reading Time: 4 mins read
A A
0
Chinese Biopharma Stocks Surge on U.S. Regulatory Openness; Innovent +6-7%, Akeso +8%, CSPC +6% as Treasury Drafts Pharma Licensing Rules
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Chinese biopharma stocks jumped Monday after report that U.S. Treasury Department is drafting rules allowing American pharmaceutical companies to continue licensing drugs from Chinese firms, excluding those related to pathogens or weaponizable biotechnology. Innovent Biologics surged 6-7%, Akeso up 8%, CSPC Pharmaceutical Group up 6%+, HUTCHMED up 3%, Sino Biopharmaceutical up 8%. Hang Seng Biotech Index gained more than 5%. Proposed approach puts biopharma on different regulatory track than AI and semiconductors, where U.S. has tightened China restrictions. Rules remain subject to change and finalization pending.
  • Chinese out-licensing boom continues despite geopolitical concerns. Almost half of U.S. deals to license drugs from overseas in 2025 were with Chinese companies per GlobalData. China completed record 81 out-licensing deals worth combined $110 billion in first half of 2026 per NMPA data cited by Nomura. Pfizer announced $10.5B partnership with Innovent in May covering 12 oncology programs—major anchor deal validating U.S. pharma appetite for Chinese drug development. Nomura noted investors appear “largely immune” to intermittent geopolitical concerns, citing Chinese companies’ strong value proposition in novel drug development at lower cost.
  • Regulatory framework supports Chinese globalization push. China made globalization of pharma/biotech companies key goal under 15th five-year plan. Against backdrop of continued out-licensing demand and now-clarified U.S. regulatory path, Nomura expects China-U.S. out-licensing deals to “ride on a high tide.” U.S. Treasury’s proposed framework validates that China pharmaceutical innovation is strategically important to American drugmakers; regulatory distinction between biopharma (permitted) vs. AI/semiconductors (restricted) signals U.S. recognizes different strategic risks.
  • Market implication: Investors repositioning Chinese biopharma exposure given regulatory clarity. Innovent’s Pfizer partnership at $10.5B scale shows de-risking of U.S. pharma partnerships. Akeso, CSPC, Sino Biopharmaceutical all positioned to benefit from accelerating U.S. licensing deal flow. Regulatory rules remain subject to change, but Treasury drafting signals high-level political willingness to preserve pharma supply chain openness despite China tensions elsewhere.

What Happened?

Chinese biopharma stocks surged Monday after Reuters report that U.S. Treasury is drafting rules allowing American pharmaceutical companies to license most drugs from Chinese firms, excluding those related to pathogens/weaponizable biotech. Innovent Biologics jumped 6-7%, Akeso surged 8%, CSPC Pharmaceutical Group up 6%+, HUTCHMED up 3%, Sino Biopharmaceutical up 8%. Hang Seng Biotech Index up 5%+. U.S. approach puts biopharma on different track from AI/semiconductors, where restrictions have tightened. Chinese out-licensing reached record $110B in H1 2026 (81 deals) per NMPA data. Almost half of 2025 U.S. pharma licensing deals were with Chinese companies per GlobalData. Pfizer’s $10.5B May partnership with Innovent (12 oncology programs) cited as anchor deal.

Why It Matters?

For Chinese biopharma shareholders, U.S. regulatory clarity enables acceleration of out-licensing deals without geopolitical uncertainty tax. For Innovent specifically, Pfizer partnership at $10.5B scale is de-risked by regulatory framework; partnership can proceed without regulatory threats. For U.S. pharma investors (Pfizer, others), China regulatory openness expands affordable drug development options and reduces innovation costs. For biotech sector broadly, Chinese biopharma’s cost advantage ($110B out-licensing speaks to market demand) validates outsourcing trend. For U.S.-China geopolitical outlook, pharma deal openness signals selective decoupling—different sectors get different treatment based on strategic risk assessment.

What’s Next?

Monitor U.S. Treasury rulemaking timeline; if rules finalized within 3-6 months, it validates regulatory openness. Watch for new pharma licensing deal announcements; if major U.S. companies announce additional Chinese partnerships, it validates market confidence in framework. Track Innovent stock momentum; if Innovent sustains gains and other Chinese biotech follows, it validates investor repositioning. Monitor geopolitical developments; if U.S.-China tensions escalate in other sectors, pharma rules could face Congressional scrutiny or revision. Watch Pfizer earnings for Innovent partnership contribution; early wins could accelerate out-licensing strategy. Track other Chinese biopharma (Akeso, CSPC) for U.S. partnership announcements; competitive deal flow would validate sector tailwind. Also monitor Chinese government policy; if 15th five-year plan pharma globalization push accelerates, it could drive more out-licensing deal flow.

Affected Tickers & Coins: 1801-HK (Innovent Biologics), 9926-HK (Akeso), 1093-HK (CSPC Pharmaceutical), HCM (HUTCHMED), 1177-HK (Sino Biopharmaceutical), PFE (Pfizer), 0941-HK (Hang Seng Biotech Index)

Source: CNBC

Previous Post

Bitcoin Above $81K After SEC Tokenized Stock Approval; NEAR Jumps 23% as NEAR Intents Zcash Swap Volume Surges 6x in One Week

Next Post

Trump Unveils ‘AI Force’ With AI Czar; U.S.-China AI Dialogue Established as Nvidia’s Huang, OpenAI’s Altman Join State Dinner Thursday

Recommended For You

Gap Cuts Its Full-Year Sales Outlook to Roughly Flat After Flat Comps, but Shares Rise More Than 11% as Old Navy Shows Progress

by Team Lumida
21 hours ago

Gap lowered its full-year sales outlook to roughly flat and cut adjusted EPS guidance, but shares rose more than 11% Friday on signs of an Old Navy turnaround.

Read more

Intuit to Sell Mailchimp to Berkshire-Backed Bending Spoons for $3.68 Billion, Less Than a Third of the $12 Billion It Paid in 2021

by Team Lumida
21 hours ago

Intuit agreed to sell Mailchimp to Bending Spoons for $3.68 billion, less than a third of the $12 billion it paid in 2021, and cut its fiscal 2027...

Read more

TPG and Corpay Agree to Buy Bill Holdings for About $6 Billion, or $63.25 a Share, With Starboard Backing the Deal

by Team Lumida
21 hours ago

TPG will buy a majority stake in Bill and Corpay a minority interest in a deal valued at about $6 billion, or $63.25 a share, the Wall Street...

Read more

Nvidia Plunges 14%, Completing Its Longest Weekly Losing Streak Since 2008, After a Report the SEC Is Exploring Accounting Issues

by Team Lumida
21 hours ago

Nvidia fell 14% on Friday and closed lower for a seventh straight week, its longest streak since 2008, after Reuters reported an SEC accounting probe.

Read more

Musk Says Ousting Huang Was Like Kicking ‘Michael Jordan Off Your Team,’ Regrets Spending at Least $474 Million on the Midterms and Says Tesla Plans a Model Y With No Steering Wheel

by Team Lumida
2 days ago
Elon Musk Reignites Legal Battle Against OpenAI and Sam Altman

At DealBook, Musk criticized Nvidia’s ousting of Jensen Huang, regretted his midterm spending and said Tesla is building a Model Y with no steering wheel.

Read more

Meta Pauses Its Class C Non-Voting Share Plan, and the $60 Billion Sale Tied to It, While a Pension Fund Lawsuit Heads to an April Trial in Delaware

by Team Lumida
2 days ago
Meta’s Content Moderation Shift: Scale Trumps Twitter-Style Risks

Meta said it will not issue Class C non-voting shares while investors including CalSTRS pursue a lawsuit, delaying a planned $60 billion share sale.

Read more

Nadella Calls Microsoft’s Outlook Outage a ‘Perfect Storm’ Caused by a Latent Bug, Saying AI-Driven ‘Patch Velocity’ Is Destabilizing Old Systems, as the Stock Sits Nearly 9% Off Its Nov. 4 High

by Team Lumida
2 days ago
Microsoft’s AI Empire: Nadella’s Bold Moves and Billion-Dollar Bets

Nadella said Microsoft should have tested before last week’s Outlook outage and warned AI-driven patching is creating instability in older systems.

Read more

Moody’s Cuts Nvidia’s Outlook to Stable From Positive on Governance Concerns After Huang’s Ouster, Saying an Upgrade of Its Aa1 Rating Is Unlikely for 12 to 18 Months

by Team Lumida
2 days ago
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears

Moody’s lowered Nvidia’s outlook to stable from positive, saying Jensen Huang’s exit has added uncertainty to its strategy and financial policies.

Read more

Palo Alto Networks Jumps 7% After Raising Its Fiscal 2027 Outlook to as Much as $14.57 Billion and Agreeing to Buy AI Startup Applied Compute for $4.5 Billion in Stock

by Team Lumida
2 days ago
Palo Alto Networks Earnings Highlights: Strong Q4 Performance and Strategic Platformization Success

Palo Alto beat estimates, lifted fiscal 2027 guidance and agreed to buy Applied Compute for $4.5 billion in stock, sending shares up more than 7%.

Read more

Anthropic Is Indicated 20% to 26% Above Its $83 IPO Price in Gray Markets, as IG Derivatives Point to a $1.35 Trillion Value and Hyperliquid Perps Trade Near $101

by Team Lumida
2 days ago

Gray markets signal a 20% to 26% pop for Anthropic, with IG implying a $1.35 trillion value and Hyperliquid perpetuals near $101 before Thursday’s debut.

Read more
Next Post
Trump Unveils ‘AI Force’ With AI Czar; U.S.-China AI Dialogue Established as Nvidia’s Huang, OpenAI’s Altman Join State Dinner Thursday

Trump Unveils 'AI Force' With AI Czar; U.S.-China AI Dialogue Established as Nvidia's Huang, OpenAI's Altman Join State Dinner Thursday

Revolut’s Nik Storonsky Targets ‘Effectively Zero Risk’ Global Bank; $115B Valuation, 80M Customers, IPO Rumors at $200B Within Two Years

Revolut's Nik Storonsky Targets 'Effectively Zero Risk' Global Bank; $115B Valuation, 80M Customers, IPO Rumors at $200B Within Two Years

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

NEAR Intents Blocks $50 Million in Bitget Hacker Swaps Via SHIELD Protocol; $503K Frozen, $166K Slipped Through; Debate Over ‘Permissionless’ Definition; THORChain Resists Blocking

Binance Hack Hit Wallets Backing Customer Assets, Leaving Ether Reserves Near 94% as Institutions Rush to Pull Funds From Exchanges

October 30, 2026
Trump Proposes 100% Tariff on Overseas-Made Movies, Citing National Security Concerns

Trump Proposes 100% Tariff on Overseas-Made Movies, Citing National Security Concerns

May 5, 2025
General Motors $GM Q2 2024 Earnings Summary

General Motors $GM Q2 2024 Earnings Summary

July 24, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018